Skip to main content

  • Pooled Cohort Study Shows Higher Device Success, Lower Safety Rates in Navitor vs Evolut and ACURATE valves

    PARIS – Higher device success but lower early safety rates are more prominent in the use of the Navitor (NAV) system in patients undergoing transcatheter aortic valve implantation (TAVI) compared with the use of the Evolut PRO/PRO+ (PRO) and ACURATE neo2 (NEO2) valves, a new pooled analysis shows. 

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details